Proteon Therapeutics
Developing pharmaceuticals for patients with renal and vascular diseases.
Launch date
Market cap
-
Enterprise valuation
€164—245m (Dealroom.co estimates May 2014.)
Waltham Massachusetts (HQ)
Financials
Estimates*
| USD | 2019 | 2020 | 2021 |
|---|---|---|---|
| Revenues | 1.0m | 7.0m | - |
| % growth | - | 600 % | - |
| Profit | (21.0m) | (31.0m) | - |
| % profit margin | (2100 %) | (443 %) | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$19.0m | Series A | ||
$12.0m | Series A | ||
$50.0m | Series B | ||
$15.2m | Series C | ||
| N/A | $4.3m | - | |
$45.0m | Series D | ||
| N/A | $70.3m | IPO | |
* | $22.0m | Post IPO Equity | |
N/A | Grant | ||
€21.0m | Post IPO Equity | ||
| Total Funding | €132m | ||
Recent News about Proteon Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.